ESR1 and neoplasm: Despite 88 % of patients having an ERα+ primary tumour, only 12 % of DTCs overall were ERα+, and as was the case with CTCs in the study by Nadal et al. [247], ERα expression was determined to be heterogeneous in 10 of 38 (26 %) patients with more than one DTC.